Skip to main content
SpringerLink
Log in

Ipilimumab/nivolumab/pembrolizumab

Various toxicities: 3 case reports

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Jiwa N, et al. A case series of hereditary neuromuscular disorders in patients with neuromuscular immune-related adverse events secondary to immune checkpoint inhibitors. Muscle and Nerve 60 (Suppl. 1): S43, Sep 2019. Available from: URL: https://onlinelibrary.wiley.com/toc/10974598/2019/60/S1 [abstract]

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ipilimumab/nivolumab/pembrolizumab. Reactions Weekly 1840, 228 (2021). https://doi.org/10.1007/s40278-021-90371-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-021-90371-z

Search

Navigation